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DNA repair by homologous recombination (HR)1 is highly suppressed in G1 cells2,3 to 
ensure that mitotic recombination occurs solely between sister chromatids4,5. Although 
many HR factors are cell cycle-regulated, the identity of the key events that are both 
necessary and sufficient to suppress recombination in G1 cells is unknown. Here we report 
that the cell cycle tightly controls the interaction of BRCA1 with PALB2-BRCA2 in order 
to constrain BRCA2 function to the S/G2 phases. We found that the BRCA1-interaction 
site on PALB2 is targeted by an E3 ubiquitin ligase composed of KEAP1, a PALB2-
interacting protein6, in complex with CUL37. PALB2 ubiquitylation suppresses its 
interaction with BRCA1 and is counteracted by the deubiquitylase USP11, which is itself 
under cell cycle control. We conclude that suppression of BRCA1-PALB2-BRCA2 complex 
assembly is a critical component of the regulatory network that prohibits recombination in 
G1 cells. Indeed, restoration of the BRCA1-PALB2 interaction combined with the 
activation of DNA end resection is sufficient to induce HR in G1, as measured by RAD51 
recruitment, unscheduled DNA synthesis and a CRISPR/Cas9-based gene targeting assay. 
The ability to induce HR in G1 cells with defined factors could represent a stepping-stone 
for the development of gene targeting applications in non-dividing cells.  
 
The breast and ovarian tumour suppressors BRCA1, PALB2 and BRCA2 promote DNA double-
strand break (DSB) repair by HR8-10. BRCA1 acts in this process minimally at two steps. Firstly, 
it promotes DNA end resection11,12, the initiating step in HR that involves the nucleolytic 
processing of breaks to produce the single-stranded (ss) DNA necessary for homology search 
and strand invasion1. Secondly, BRCA1 interacts with PALB213-15 to direct the recruitment of 
BRCA213 and RAD5116,17 to DSB sites. The accumulation of BRCA1 on the chromatin that 
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flanks DSB sites is strikingly suppressed in G1 cells18, reminiscent of the potent inhibition of HR 
in this phase of the cell cycle. Since the inhibition of BRCA1 recruitment in G1 is dependent on 
the 53BP1 and RIF1 proteins18,19, two inhibitors of end-resection18-22, this regulation of BRCA1 
was originally viewed in light of its function in stimulating DNA end processing. 
 However, as BRCA1 is also involved in promoting the recruitment of BRCA2 through its 
interaction with PALB213-15, we asked whether inducing BRCA1 recruitment to DSB sites in G1, 
through mutation of 53BP1 by genome editing (53BP1Δ;  Extended Data Fig. 1a-c) also resulted 
in BRCA2 accumulation into ionizing radiation (IR)-induced foci. To our surprise, we found that 
in contrast to BRCA1 neither BRCA2 nor PALB2 are recruited to G1 DSB sites in U-2-OS 
(U2OS) cells lacking 53BP1 at IR doses ranging from 2 to 20 Gy (Fig. 1ab and Extended Data 
Fig. 1de). Since BRCA1 and PALB2 interact directly13,14, this result suggested that G1 cells may 
block BRCA2 recruitment by suppressing the BRCA1-PALB2 interaction. Indeed, while PALB2 
interacts with BRCA2 irrespective of cell cycle position, it interacted efficiently with BRCA1 
only during S phase (Fig. 1c). The presence of DNA damage led to the loss of the residual 
PALB2-BRCA1 interaction in G1 whereas it had little impact on the assembly of the BRCA1-
PALB2-BRCA2 complex in S phase (Fig. 1c). Since all proteins were expressed in G1 (Fig. 1c), 
our results suggest that the assembly of the BRCA1-PALB2-BRCA2 complex is controlled 
during the cell cycle, possibly to restrict the accumulation of BRCA2 at DSB sites to the S/G2 
phases.  
We confirmed these results using a single-cell assay assessing the co-localization, at an 
integrated LacO array23, of an mCherry-tagged LacR-BRCA1 fusion protein with GFP-tagged 
PALB2 (Extended Data Fig. 2a). This LacR/LacO system recapitulated the cell cycle-dependent 
and DNA damage-sensitive BRCA1-PALB2 interaction (Extended Data Fig. 2b) and enabled us 
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to determine that sequences on PALB2, located outside its N-terminal BRCA1-interaction 
domain (residues 1-50) were responsible for the cell cycle-dependent regulation of its association 
with BRCA1 (Extended Data Fig. 2cd). Further deletion mutagenesis identified a single region, 
encompassed within residues 46-103 in PALB2 (Extended Data Fig. 2ef) responsible for the cell 
cycle-dependent regulation of the BRCA1-PALB2 interaction. This region corresponds to the 
interaction site for KEAP16, identifying this protein as a candidate regulator of the BRCA1-
PALB2 interaction. 
KEAP1 is a substrate adaptor for a CRL3 E3 ubiquitin (Ub) ligase that targets the 
antioxidant regulator NRF2 for proteasomal degradation24 and recognizes an “ETGE” motif on 
both PALB2 and NRF2 through its KELCH domain6. Depletion of KEAP1 from 53BP1Δ cells, 
or deletion of the ETGE motif in full-length PALB2 (PALB2 ΔETGE) induced G1-phase 
PALB2 IR-induced focus formation (Fig 1d and Extended Data Fig. 3a). Furthermore, in cells in 
which KEAP1 was inactivated by genome editing (KEAP1Δ, Extended Data Fig. 3b) we detected 
a stable BRCA1-PALB2-BRCA2 complex in both G1 and S phases (Fig. 1e). KEAP1 is 
therefore an inhibitor of the BRCA1-PALB2 interaction. 
CUL3 also interacts with PALB2 (Extended Data Fig. 3c) and its depletion in 53BP1Δ 
U2OS cells de-repressed PALB2 IR-induced foci in G1 (Fig. 1d and Extended Data Fig. 3a). 
Furthermore, in G1-synchronized KEAP1Δ cells, expression of a CUL3-binding deficient 
KEAP1 protein that lacks its BTB domain (ΔBTB) failed to suppress the BRCA1-PALB2 
interaction, unlike its wild type counterpart (Fig. 1f). These results suggest that KEAP1 recruits 
CUL3 to PALB2 to suppress its interaction with BRCA1. 
Using the LacR/LacO system and co-immunoprecipitation assays, we found that a mutant 
of PALB2 lacking all 8 lysine residues in the BRCA1-interaction domain (PALB2-KR; Fig 2a) 
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could interact with BRCA1 irrespective of cell cycle position (Fig. 2b and Extended Data Fig. 
3de). Further mutagenesis identified residues 20, 25 and 30 in PALB2 as critical for the 
suppression of the BRCA1-PALB2 interaction since re-introduction of these lysines in the 
context of PALB2-KR (yielding PALB2-KR/K3; Fig 2a) led to the suppression of BRCA1-
PALB2-BRCA2 complex assembly in G1 cells (Fig. 2b and Extended Data Fig. 3d). Together, 
these results suggested a model whereby PALB2-bound KEAP1 forms an active CRL3 complex 
that ubiquitylates the PALB2 N-terminus to suppress its interaction with BRCA1. 
While PALB2 ubiquitylation can be detected in cells (Extended Data Fig. 4a), the lysine-
rich nature of the PALB2 N-terminus has so far precluded us from unambiguously mapping in 
vivo ubiquitylation sites on Lys20, 25 or 30. However we could detect ubiquitylation on Lys16 
and Lys43 by mass spectrometry, indicating that the PALB2 N-terminus is ubiquitylated 
(Extended Data Fig. 4b). In a complementary set of experiments, PALB2 targeted to the LacO 
array induced immunoreactivity to conjugated ubiquitin (Fig 2cd and Extended Data Fig. 4c). Ub 
colocalization with PALB2 was highest in G1, depended on the KEAP1-interaction motif and the 
presence of the Lys20/25/30 residues (Fig 2d and Extended Data Fig. 4c), consistent with a 
model that PALB2 is ubiquitylated on those sites in G1 cells. Indeed, we could readily 
reconstitute ubiquitylation of the N-terminus of PALB2 (residues 1-103; fused to a HA epitope 
tag), by recombinant CRL3-KEAP1, in a manner that depended on the KEAP1-interaction 
domain of PALB2 (Fig. 2e) and we unambiguously identified Lys25 and Lys30 as being 
ubiquitylated by KEAP1 in vitro by mass spectrometry (Extended Data Fig. 5). 
Ubiquitylation of PALB2 by CRL3-KEAP1 inhibited its interaction with BRCA1, which 
was more obvious with the highly modified forms of PALB2 due to the presence of ubiquitylated 
lysines outside the BRCA1-interaction domain (Fig. 2f). In order to specifically test whether 
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ubiquitylation of a single lysine residue of the three identified as critical inhibited the interaction 
with BRCA1, we used dichloroacetone crosslinking to install a single ubiquitin moiety at 
position 20 or 45 (yielding PALB2-KC20-Ub and PALB2-KC45-Ub). Ubiquitylation of PALB2 
at position 20 completely suppressed its interaction with BRCA1 whereas modification of 
residue 45 had no impact on the interaction (Extended Data Fig. 6). Together, these results 
indicate that PALB2 ubiquitylation on specific sites on its N-terminus prevents its interaction 
with BRCA1. 
Since neither the activity of the CRL3-KEAP1 E3 ligase (Extended Data Fig. 7) nor the 
interaction of CRL3-KEAP1 with PALB2 (Extended Data Fig. 3c) are regulated by the cell 
cycle, we considered the possibility that deubiquitylation of PALB2 might be regulated in a cell 
cycle-dependent manner. KEAP1 physically interacts with USP1125, a deubiquitylase that also 
interacts with BRCA226 and PALB2 (Extended Data Fig. 8a). USP11 depletion impairs gene 
conversion27 (Extended Data Fig. 8b) and results in hypersensitivity to PARP inhibition27 
identifying it as an HR regulator of unknown function. Co-immunoprecipitation experiments 
confirmed that USP11 and its catalytic activity were necessary for the formation of a stable 
BRCA1-PALB2-BRCA2 complex, especially in the presence of DNA damage (Fig. 3a and 
Extended Data Fig. 8cd).  
If USP11 antagonizes PALB2 ubiquitylation by CRL3-KEAP1, then removal of KEAP1 
(or CUL3) should reverse the phenotypes imparted by loss of USP11. Indeed, deletion of KEAP1 
restored PARPi resistance and the BRCA1-PALB2 interaction in USP11 knockout cells prepared 
by genome editing (USP11Δ) (Fig 3bc and Extended Data Fig. 8c). Likewise, depletion of CUL3 
or KEAP1 reversed the gene conversion defect of USP11-depleted cells (Extended Data Fig. 9a). 
Introduction of the PALB2-KR mutant restored its interaction with BRCA1 and reversed PARPi 
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sensitivity in USP11Δ cells in a manner that depended on Lys20/25/30 (Extended Data Fig. 9bc). 
Since recombinant USP11 can directly de-ubiquitylate PALB2 (1-103) (Fig. 3d), these results 
suggest that USP11 promotes the assembly of the BRCA1-PALB2-BRCA2 complex by 
reversing ubiquitylation on the PALB2 Lys20/25/30 residues. 
We observed that USP11 turns over rapidly in G1 cells and interacts poorly with PALB2 
in this phase of the cell cycle (Extended Data Fig. 10ab). However the most direct evidence that 
USP11 was under cell cycle regulation consists of the observation that there is a rapid loss of 
USP11 upon DNA damage induction, specifically in G1 phase (Fig 3e and Extended Data Fig. 
10bc). The destabilization of USP11 following IR treatment is dependent on ATM signalling, 
whereas it is ATR-dependent following UV irradiation (Extended Data Fig. 10de). The drop in 
USP11 steady-state levels in G1 is the result of proteasomal degradation (Extended Data Fig. 
10f). A CRL4 complex is most likely responsible for controlling the stability of USP11 as 
treatment with MLN492, a pan-CRL inhibitor28 (Extended Data Fig. 10g), or depletion of CUL4 
protected USP11 from DNA damage-induced degradation (Fig. 3f). CUL4 depletion led to 
BRCA2 and PALB2 IR-induced focus formation in G1 53BP1Δ cells (Fig. 3g and Extended 
Data Fig. 11), consistent with the regulation of USP11 by a CRL4 complex acting as the 
upstream signal that ultimately controls BRCA1-PALB2-BRCA2 complex assembly. 
While deletion of 53BP1 produces low levels of ssDNA in G1 cells29, combining the 
53BP1Δ mutation with depletion of KEAP1 did not produce extraction-resistant RAD51 IR-
induced foci, suggesting little-to-no RAD51 nucleofilament formation. We surmised that ssDNA 
formation remained insufficient in those cells and thus took advantage of the phosphomimetic 
T847E mutant of CtIP that promotes resection in G1 cells30. Unlike wild type CtIP, introduction 
of CtIP-T847E into 53BP1Δ cells depleted of KEAP1 induced RAD51 IR-induced focus 
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formation in G1 cells (Fig 4ab and Extended Data Fig. 12ab) along with unscheduled DNA 
synthesis (Fig 4c). These results suggested that the steps downstream of RAD51 nucleofilament 
formation, i.e. strand invasion, D-loop formation and DNA synthesis, could be activated in G1. 
To test whether productive HR could also be activated in G1 we employed a 
CRISPR/Cas9-stimulated gene targeting assay in which the insertion of the coding sequence for 
the mClover fluorescent protein at the 5’ of the LAMIN A (LMNA) or PML genes was monitored 
by microscopy or flow cytometry (Fig 4d and Extended Data Fig. 12cd), with the latter method 
enabling the gating of cells with a defined DNA content (such as G1 cells). We also established 
synchronization protocols in which G1 cells obtained after release from a thymidine block were 
arrested in G1 by lovastatin treatment2 for 24 h (Extended Data Fig. 12ef). With this system in 
hand, we first ascertained that gene targeting at the LMNA locus, was dependent on BRCA1-
PALB2-BRCA2 complex assembly (Extended Data Fig. 13a), and that gene targeting by HR was 
highly suppressed in G1 (Fig 4e).  
The combined activation of resection and BRCA1 recruitment to DSB sites (i.e. in 
53BP1Δ cells expressing CtIP-T847E) was insufficient to stimulate gene targeting at either the 
LMNA or the PML locus in G1 cells (Fig 4f and Extended Data Fig. 13bc). However, when the 
BRCA1-PALB2 interaction was restored in resection-competent G1 cells using either KEAP1 
depletion or expression of the PALB2-KR mutant, we detected a robust increase in gene 
targeting events at both loci (Fig 4f and Extended Data Fig. 13bc). We note however that the 
gene-targeting frequencies of G1 cells remained lower than those of asynchronously dividing 
cells, suggesting an incomplete activation of HR. 53BP1 inactivation and the expression of CtIP-
T847E were both necessary for G1 HR (Extended Data Fig. 14), indicating that the simultaneous 
activation of end resection and BRCA2 recruitment to DSB sites were both necessary and 
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sufficient to activate unscheduled recombination in this phase of the cell cycle.  
We conclude that the regulation of BRCA1-PALB2-BRCA2 complex assembly is a key 
node in the cell cycle control of DSB repair by HR. This regulation converges on the BRCA1-
interaction site on PALB2 and is enforced by the opposing activities of the E3 ligase CRL3-
KEAP1 and the deubiquitylase USP11, with the latter being antagonized in G1 by a CRL4 
complex (Fig. 4g). In this model, the stabilization of USP11 in S phase licenses the recruitment 
of PALB2-BRCA2 and the subsequent loading of RAD51 at DSB sites. Our studies also 
demonstrate that the suppression of HR in G1 cells is largely reversible and that it involves the 
combined suppression of end resection and BRCA2 recruitment to DSB sites. As most of the 
cells in the human body are in G0/G1 phase and thus refractory to gene targeting, the 
manipulations described herein may spur the development of genome editing methods that 
enable therapeutic gene targeting in a wider variety of tissues. 
 
Acknowledgments 
We are grateful to Rachel Szilard for critical reading of the manuscript, and also to Dara Lo, 
Marella Canny and Jordan Young for help with experiments on the project. We also thank Brett 
Larsen and Monika Tulcholska for technical support with the mass spectrometry, Jeremy Stark 
for the U2OS DR-GFP cells, Roger Greenberg for the U2OS 256 cells, Philip Reaper for the VE-
821 inhibitor, Frank Sicheri for recombinant CDC34 and TEV protease, Feng Shao for the 
KEAP1 bacterial expression vector, David Cortez for the USP11 cDNA, Dmitris Xirodimas for 
the NEDD8 cDNA and Aude Echalier for the DEN1 cDNA. AO receives a post-doctoral 
fellowship from the CIHR; SMN receives a postdoctoral fellowship from the KWF; MDW holds 
a long-term HFSP fellowship; AS receives a graduate fellowship from OGS. JP was supported 
 10 
by a trainee award from the Beatrice Hunter Cancer Research Institute (BHCRI) with funds 
provided by the Harvey Graham Cancer Research Fund as part of the Terry Fox Foundation 
Strategic Health Research Training Program in Cancer Research at CIHR. GD is a Senior 
Scientist of the BHCRI. DD is the Thomas Kierans Chair in Mechanisms of Cancer 
Development and a Canada Research Chair (Tier 1) in the Molecular Mechanisms of Genome 
Integrity. This work was supported by CIHR grants MOP89754 (to DD) and MOP84260 (to GD) 
and a Grant-in-Aid from the Krembil Foundation (to DD).  
 
Author contributions 
AO initiated the project and carried out most of the experiments. SMN carried out in vitro 
ubiquitylation experiments, pull-downs and mass spectrometry. MDW produced recombinant 
KEAP1 and advised on ubiquitylation biochemistry. SL produced the 53BP1Δ cells. RIE 
produced active CUL3-RBX1. AS contributed to experiments on the regulation of USP11 
degradation. MM helped AO on USP11 experiments. BX contributed critical PALB2 reagents 
and advice. JP and GD provided the vectors for the gene targeting assays. MP supervised RIE. 
DD supervised the project and wrote the manuscript with AO and with input from the other 
authors. 
 
Correspondence and requests should be addressed to durocher@lunenfeld.ca 
 
 
The authors declare no competing financial interests. 
 
 
REFERENCES 
 
1 Jasin, M. & Rothstein, R. Repair of strand breaks by homologous recombination. Cold 
Spring Harb Perspect Biol 5, a012740, doi:10.1101/cshperspect.a012740 (2013). 
 11 
2 Hartlerode, A., Odate, S., Shim, I., Brown, J. & Scully, R. Cell cycle-dependent induction 
of homologous recombination by a tightly regulated I-SceI fusion protein. PLoS One 6, 
e16501, doi:10.1371/journal.pone.0016501 (2011). 
3 Rothkamm, K., Kruger, I., Thompson, L. H. & Lobrich, M. Pathways of DNA double-
strand break repair during the mammalian cell cycle. Mol Cell Biol 23, 5706-5715 
(2003). 
4 Kasparek, T. R. & Humphrey, T. C. DNA double-strand break repair pathways, 
chromosomal rearrangements and cancer. Semin Cell Dev Biol 22, 886-897, 
doi:10.1016/j.semcdb.2011.10.007 (2011). 
5 Panier, S. & Durocher, D. Push back to respond better: regulatory inhibition of the DNA 
double-strand break response. Nature reviews. Molecular cell biology, 
doi:10.1038/nrm3659 (2013). 
6 Ma, J. et al. PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and 
function. Mol Cell Biol 32, 1506-1517, doi:10.1128/MCB.06271-11 (2012). 
7 Genschik, P., Sumara, I. & Lechner, E. The emerging family of CULLIN3-RING 
ubiquitin ligases (CRL3s): cellular functions and disease implications. EMBO J 32, 2307-
2320, doi:10.1038/emboj.2013.173 (2013). 
8 Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: different roles in a common 
pathway of genome protection. Nat Rev Cancer 12, 68-78, doi:10.1038/nrc3181 
nrc3181 [pii] (2011). 
9 Li, M. L. & Greenberg, R. A. Links between genome integrity and BRCA1 tumor 
suppression. Trends Biochem Sci, doi:S0968-0004(12)00092-8 [pii] 
10.1016/j.tibs.2012.06.007 (2012). 
10 Park, J. Y., Zhang, F. & Andreassen, P. R. PALB2: The hub of a network of tumor 
suppressors involved in DNA damage responses. Biochim Biophys Acta 1846, 263-275, 
doi:10.1016/j.bbcan.2014.06.003 (2014). 
11 Schlegel, B. P., Jodelka, F. M. & Nunez, R. BRCA1 promotes induction of ssDNA by 
ionizing radiation. Cancer Res 66, 5181-5189, doi:66/10/5181 [pii] 
10.1158/0008-5472.CAN-05-3209 (2006). 
12 Stark, J. M., Pierce, A. J., Oh, J., Pastink, A. & Jasin, M. Genetic steps of mammalian 
homologous repair with distinct mutagenic consequences. Mol Cell Biol 24, 9305-9316, 
doi:24/21/9305 [pii] 
10.1128/MCB.24.21.9305-9316.2004 (2004). 
13 Zhang, F. et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr 
Biol 19, 524-529, doi:S0960-9822(09)00723-4 [pii] 
10.1016/j.cub.2009.02.018 (2009). 
14 Sy, S. M., Huen, M. S. & Chen, J. PALB2 is an integral component of the BRCA 
complex required for homologous recombination repair. P Natl Acad Sci USA 106, 7155-
7160, doi:10.1073/pnas.0811159106 (2009). 
15 Simhadri, S. et al. Male Fertility Defect Associated with Disrupted BRCA1-PALB2 
Interaction in Mice. J Biol Chem 289, 24617-24629, doi:10.1074/jbc.M114.566141 
(2014). 
16 Bhattacharyya, A., Ear, U. S., Koller, B. H., Weichselbaum, R. R. & Bishop, D. K. The 
breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 
and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 
275, 23899-23903, doi:10.1074/jbc.C000276200 
 12 
C000276200 [pii] (2000). 
17 Zhang, F., Bick, G., Park, J. Y. & Andreassen, P. R. MDC1 and RNF8 function in a 
pathway that directs BRCA1-dependent localization of PALB2 required for homologous 
recombination. J Cell Sci 125, 6049-6057, doi:10.1242/jcs.111872 (2012). 
18 Escribano-Diaz, C. et al. A Cell Cycle-Dependent Regulatory Circuit Composed of 
53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice. Molecular cell 
49, 872-883, doi:10.1016/j.molcel.2013.01.001 (2013). 
19 Feng, L., Fong, K. W., Wang, J., Wang, W. & Chen, J. RIF1 counteracts BRCA1-
mediated end resection during DNA repair. The Journal of biological chemistry 288, 
11135-11143, doi:10.1074/jbc.M113.457440 (2013). 
20 Chapman, J. R. et al. RIF1 Is Essential for 53BP1-Dependent Nonhomologous End 
Joining and Suppression of DNA Double-Strand Break Resection. Mol Cell, doi:S1097-
2765(13)00003-8 [pii] 
10.1016/j.molcel.2013.01.002 (2013). 
21 Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells 
by blocking resection of DNA breaks. Cell 141, 243-254, doi:S0092-8674(10)00285-0 
[pii] 
10.1016/j.cell.2010.03.012 (2010). 
22 Zimmermann, M., Lottersberger, F., Buonomo, S. B., Sfeir, A. & de Lange, T. 53BP1 
Regulates DSB Repair Using Rif1 to Control 5' End Resection. Science, 
doi:science.1231573 [pii] 
10.1126/science.1231573 (2013). 
23 Tang, J. et al. Acetylation limits 53BP1 association with damaged chromatin to promote 
homologous recombination. Nature structural & molecular biology, 
doi:10.1038/nsmb.2499 (2013). 
24 Taguchi, K., Motohashi, H. & Yamamoto, M. Molecular mechanisms of the Keap1-Nrf2 
pathway in stress response and cancer evolution. Genes Cells 16, 123-140, 
doi:10.1111/j.1365-2443.2010.01473.x (2011). 
25 Sowa, M. E., Bennett, E. J., Gygi, S. P. & Harper, J. W. Defining the human 
deubiquitinating enzyme interaction landscape. Cell 138, 389-403, 
doi:10.1016/j.cell.2009.04.042 (2009). 
26 Schoenfeld, A. R., Apgar, S., Dolios, G., Wang, R. & Aaronson, S. A. BRCA2 is 
ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits 
prosurvival function in the cellular response to DNA damage. Mol Cell Biol 24, 7444-
7455, doi:10.1128/MCB.24.17.7444-7455.2004 
24/17/7444 [pii] (2004). 
27 Wiltshire, T. D. et al. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition 
identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand 
break repair. J Biol Chem 285, 14565-14571, doi:M110.104745 [pii] 
10.1074/jbc.M110.104745 (2010). 
28 Brownell, J. E. et al. Substrate-assisted inhibition of ubiquitin-like protein-activating 
enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol 
Cell 37, 102-111, doi:10.1016/j.molcel.2009.12.024 (2010). 
29 Yamane, A. et al. RPA accumulation during class switch recombination represents 5'-3' 
DNA-end resection during the S-G2/M phase of the cell cycle. Cell Rep 3, 138-147, 
doi:10.1016/j.celrep.2012.12.006 (2013). 
 13 
30 Huertas, P. & Jackson, S. P. Human CtIP mediates cell cycle control of DNA end 
resection and double strand break repair. The Journal of biological chemistry 284, 9558-
9565, doi:10.1074/jbc.M808906200 (2009). 
31 Fradet-Turcotte, A. et al. 53BP1 is a reader of the DNA-damage-induced H2A Lys 15 
ubiquitin mark. Nature 499, 50-54, doi:10.1038/nature12318 (2013). 
32 Enchev, R. I., Schreiber, A., Beuron, F. & Morris, E. P. Structural insights into the COP9 
signalosome and its common architecture with the 26S proteasome lid and eIF3. 
Structure 18, 518-527, doi:10.1016/j.str.2010.02.008 (2010). 
33 Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protocols 8, 
2281-2308, doi:10.1038/nprot.2013.143 (2013). 
34 Xia, B. et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, 
PALB2. Mol Cell 22, 719-729, doi:10.1016/j.molcel.2006.05.022 (2006). 
35 Orthwein, A. et al. Mitosis inhibits DNA double-strand break repair to guard against 
telomere fusions. Science 344, 189-193, doi:10.1126/science.1248024 (2014). 
36 Panier, S. et al. Tandem protein interaction modules organize the ubiquitin-dependent 
response to DNA double-strand breaks. Molecular cell 47, 383-395, 
doi:10.1016/j.molcel.2012.05.045 (2012). 
37 Juang, Y. C. et al. OTUB1 co-opts Lys48-linked ubiquitin recognition to suppress E2 
enzyme function. Mol Cell 45, 384-397, doi:10.1016/j.molcel.2012.01.011 
S1097-2765(12)00077-9 [pii] (2012). 
38 Cui, J. et al. Glutamine deamidation and dysfunction of ubiquitin/NEDD8 induced by a 
bacterial effector family. Science 329, 1215-1218, doi:10.1126/science.1193844 (2010). 
39 Enchev, R. I. et al. Structural basis for a reciprocal regulation between SCF and CSN. 
Cell Rep 2, 616-627, doi:10.1016/j.celrep.2012.08.019 (2012). 
40 Long, L., Furgason, M. & Yao, T. Generation of nonhydrolyzable ubiquitin-histone 
mimics. Methods 70, 134-138, doi:10.1016/j.ymeth.2014.07.006 (2014). 
 
 14 
FIGURE LEGENDS 
 
Figure 1. Inhibition of the BRCA1-PALB2 interaction in G1 is CRL3-KEAP1-dependent.  
a, U2OS cells synchronized in G1 after release from a double-thymidine block were irradiated (2 
Gy) and processed for γ-H2AX, BRCA1 and BRCA2 immunofluorescence. b, Quantitation of 
the experiment shown in a and Extended Data Fig. 1d. ASN=asynchronously dividing cells. WT, 
wild type (mean ± s.d., N=3). c, Immunoprecipitation (IP) of endogenous PALB2 from extracts 
prepared from mock- or X-irradiated 293T cells synchronized in S or G1 phases. IP with normal 
IgG was performed as a control. Cyclin A (CCNA) immunoblotting demonstrates the efficacy of 
the synchronization. d, Quantitation of the experiment shown in Extended Data Fig. 3a. 
53BP1Δ U2OS cells were transfected with the indicated GFP-PALB2 vectors and siRNAs and 
irradiated (20 Gy) before being processed for fluorescence microscopy. Cells were also stained 
with a Cyclin A (CCNA) antibody to determine cell cycle position (mean ± s.d., N=3). e, IP of 
PALB2 from extracts prepared from synchronized and irradiated 293T cells of the indicated 
genotypes. IP with normal IgG was performed as a control. f, 293T cells with the indicated 
genotypes were transfected with the indicated HA-KEAP1 constructs, synchronized in G1 or S 
phases and irradiated. Cells were processed for PALB2 immunoprecipitation (IP). EV, empty 
vector. 
 
Figure 2. Ubiquitylation of PALB2 prevents BRCA1-PALB2 interaction. a, Sequence of the 
N-terminal region of PALB2 and the different mutants used. b, 293T cells were transfected with 
the indicated GFP-PALB2 constructs and synchronized in G1 or S phase. Cells were processed 
for GFP immunoprecipitation (IP). c, Schematic of the LacO/LacR chromatin-targeting system 
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and the in vivo quantification of ubiquitylated PALB2. d, U2OS 256 cells were transfected with 
the indicated mCherry-LacR-PALB2 vectors. Cells were processed for quantitation of FK2 
fluorescence at the mCherry focus. Each circle represents a cell analyzed from 3 independent 
experiments and the bar is at the median. Cells were also stained with a Cyclin A antibody to 
determine cell cycle position. *** denotes P <0.001 between the G1 and S/G2 conditions 
calculated with a one-way ANOVA with Bonferroni correction. e, In vitro ubiquitylation of the 
indicated HA-tagged PALB2 protein by KEAP1 and the NEDDylated CUL3/RBX1 complex. 
CDC34 was used as the E2 conjugating enzyme. f, Pulldown assay of in vitro ubiquitylated HA-
PALB2 (1-103) incubated with MBP or MBP-BRCA1-CC. I: input, PD: pulldown, FT: flow-
through. 
 
Figure 3. USP11 opposes the activity of CRL3-KEAP1. a, 293T cells with the indicated 
genotypes were transfected with the indicated GFP-USP11 constructs and treated with CPT. 
Cells were processed for normal IgG control or PALB2 immunoprecipitation. CS, C318S. b, 
Clonogenic survival assays of 293T cells of the indicated genotypes in the presence of olaparib 
(mean ± s.d., N=4).  c, 293T cells of the indicated genotypes were treated with CPT and then 
processed for normal IgG or PALB2  immunoprecipitation (IP). d, HA-tagged PALB2 (1-103) 
was ubiquitylated in vitro with lysine-less Ub, and then subjected to deubiquitylation using 
increasing concentrations of GST-USP11 or its catalytically-inactive mutant (CS). USP2 was 
used as a control. e, U2OS cells synchronized in the indicated cell cycle phases were irradiated 
with a 20 Gy dose, harvested at the indicated time points and processed for USP11 and actin 
immunoblotting. f, U2OS cells were transfected with the indicated siRNAs, irradiated and 
processed for immunoblotting. g, 53BP1Δ U2OS cells were transfected with the indicated 
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siRNA, synchronized in G1 by release from a double-thymidine block, and irradiated (20 Gy) 
before being processed for fluorescence microscopy. The percentage of cells with more than 5 γ-
H2AX-colocalizing BRCA2 foci is indicated (mean ± s.d., N=3).   
 
Figure 4. Reactivation of HR in G1 phase. a, Quantification of wild type (WT) and 
53BP1Δ U2OS cells co-transfected with non-targeting (CTRL) or KEAP1 siRNAs and vectors 
expressing WT CtIP or the T847E (TE) mutant that ells were synchronized in G1, irradiated (2 
Gy) and processed for γ-H2AX and RAD51 immunofluorescence (mean ± s.d., N=3). b, 
Representative micrograph from the quantification shown in a. c, U2OS 53BP1Δ cells were 
synchronized in G1, supplemented with BrdU, irradiated (2 Gy) and processed for γ-H2AX and 
BrdU immunofluorescence. The percentage of cells with more than 5 γ-H2AX-colocalizing 
BrdU foci is indicated (mean ± s.d., N=3). d, Schematic of the assay in which the open reading 
frame of mClover is inserted at the 5’ end of the coding sequence of the LMNA (or PML) gene 
following a CRISPR/Cas9-mediated DSB. e,  Quantitation of gene targeting efficiency at the 
LMNA locus in asynchronously dividing (ASN) and G1-arrested U2OS cells. Gene targeting 
events were detected by flow cytometry (mean ± s.d., N=3). f, Gene targeting efficiency at the 
LMNA locus measured by flow cytometry in G1-arrested cells transfected with the indicated 
siRNA or a PALB2-KR expression vector (mean ± s.d., N=3). g, Model of the cell-cycle 
regulated assembly of the BRCA1-PALB2-BRCA2 complex. 
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EXTENDED DATA FIGURE LEGENDS 
 
Extended Data Figure 1 | Related to Fig. 1.  a, Schematic representation of human 53BP1 gene 
organization and targeting sites of sgRNAs used. Boxes indicate exons (E: yellow, coding 
sequence; brown, untranslated regions (UTRs)). The indels introduced by CRISPR/Cas9 and 
their respective frequencies are indicated. b, Wild-type (WT) and 53BP1Δ and U2OS cells were 
mock- or X-irradiated (10 Gy) before being processed for 53BP1 fluorescence microscopy. 
DAPI was used to stain DNA and trace the outline of the nucleus. c, Wild-type (WT) and 
53BP1Δ U2OS cells were processed for 53BP1 immunoblotting. Tubulin was used as a loading 
control. d, Wild-type (WT) and 53BP1Δ  U2OS cells either synchronized in G1 following a 
double-thymidine block and release or asynchronously dividing (ASN), were irradiated (2 Gy) 
and processed for γ-H2AX, PALB2, BRCA2 and BRCA1,immunofluorescence. The 
micrographs relating to BRCA1 and BRCA2 staining in G1 are found in Fig. 1a. e, Wild-type 
(WT) and 53BP1Δ U2OS cells synchronized in G1 after release from a double-thymidine block 
were irradiated (20 Gy) and processed for γ-H2AX, BRCA1 and BRCA2 immunofluorescence. 
On the left are representative micrographs for the G1-arrested cells and the quantitation of the 
full experiment is shown on the right (mean ± s.d., N=3). 
 
Extended Data Figure 2 | Related to Fig. 1.  a, Schematic of the LacO/LacR chromatin-
targeting system. b, U2OS 256 cells were transfected with the indicated mCherry-LacR and 
GFP-fusions. GFP fluorescence was measured at the site of the LacO array-localized mCherry 
focus. Each circle represents one cell analysed and the bar is at the median. Cells were also 
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stained with a Cyclin A  antibody to determine cell cycle position (N=3).  c, Representative 
micrographs of U2OS 256 cells transfected with the indicated mCherry-LacR and GFP-fusions; 
data is quantified in d. d, Quantification of U2OS 256 cells transfected with the indicated 
mCherry-LacR and GFP-fusion to tether either BRCA1 or PALB2 to the LacO array. BRCA1-
CC: coiled-coil domain interacting with PALB2 (N=3). e, Schematic representation of PALB2 
architecture and its major interacting proteins. f, Quantification of U2OS 256 cells transfected 
with the indicated GFP-PALB2 mutants and mCherry-LacR-BRCA1-CC. Cells were also stained 
with a Cyclin A  antibody to determine cell cycle position (N=3). 
 
Extended Data Figure 3 | Related to Fig. 1 and 2. a, Representative micrographs of the 
experiment shown in Fig. 1d. b, Schematic representation of human KEAP1 gene organization 
and targeting sites of sgRNAs used as described in Extended Data Fig.1. a. The indels introduced 
by CRISPR/Cas9 and their respective frequencies are indicated. c, Immunoprecipitation (IP) of 
PALB2 from extracts prepared from irradiated 293T cells. IP with normal IgG was performed as 
a control. d, Quantification of U2OS 256 cells transfected with the indicated GFP-PALB2 
mutants and mCherry-LacR-BRCA1. Cells were also stained with a Cyclin A antibody to 
determine cell cycle position (N=3). e, Quantification of U2OS 256 cells transfected with GFP-
PALB2 and the indicated mCherry-LacR-BRCA1-CC (CC: coiled-coil) mutants. Cells were also 
stained with a Cyclin A antibody to determine cell cycle position (N=3). This panel shows that 
the sole lysine in the PALB2-interaction motif is not involved in the cell cycle regulation of the 
PALB2-BRCA1 interaction. 
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Extended Data Figure 4 | Related to Fig. 2. a, HEK293 Flp-In T-REX cells expressing 
doxycycline (DOX)-inducible His6-Ub were transfected with the indicated siRNAs. Cells were 
processed for Ni-NTA pull-down (IP). b, 293T cells transfected with an siRNA targeting USP11 
and a Flag-PALB2 expression vector were processed for Flag immunoprecipitation followed by 
mass spectrometry. Representative MS2 spectra of tryptic diglycine (diG)-PALB2 peptides 
identified and shown (K16, top; K43, bottom). c, Representative micrographs of the experiment 
shown in Fig. 2d. Scale bar = 5 µm.   
 
Extended Data Figure 5 | Related to Fig. 2. HA-PALB2 (1-103) was subjected to in vitro 
ubiquitylation reactions that lacked (left panels) or included (right panels) CUL3. Representative 
fragmentation spectra of tryptic peptides from the reaction products are shown. For each peptide, 
the traces from top to bottom show: total ion current; basepeak chromatograms of the heavy- and 
light-labeled peptide mass, respectively; representative MS/MS fragmentation spectra of the 
heavy- and light-labeled peptide, respectively. The heavy-labeled amino acid is indicated by an 
asterisk (*).  
 
Extended Data Figure 6 | Related to Fig. 2. Site-specific chemical ubiquitylation of PALB2 (1-
103) at residue 20 (PALB2-KC20-Ub) and 45 (PALB2-KC45-Ub) was carried out by 
dichloroacetone linking. The resulting ubiquitylated PALB2 polypeptides along with their 
unmodified counterparts were subjected to pulldown with a fusion of MBP with the coiled-coil 
domain of BRCA1 (MBP-BRCA1-CC). I, input; PD, pulldown. Asterisk (*) indicates a non-
specific band. 
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Extended Data Figure 7 | Related to Fig. 3.  a, Wild-type and KEAP1Δ 293T cells were treated 
with cycloheximide (CHX) for the indicated time and then processed for NRF2 and KEAP1 
immunoblotting. Actin levels were also determined as a loading control. 
 
Extended Data Figure 8 | Related to Fig. 3. a, Immunoprecipitation (IP) of USP11 from 
extracts prepared from 293T cells that were or were not treated with camptothecin (CPT; 200 
nM). IP with normal IgG was performed as a control. b, U2OS DR-GFP cells were transfected 
with the indicated siRNAs. 24 h post-transfection, cells were further transfected with the 
indicated siRNA-resistant USP11 expression vectors (WT=wild type; CA= C318A and CS= 
C318S catalytically-dead mutants) or an empty vector (EV), with or without an I-SceI expression 
vector. The percentage of GFP-positive cells was determined 48 h post-plasmid transfection for 
each condition and was normalized to the I-SceI + non-targeting (siCTRL) condition (mean ± 
s.d., N=3). c, Schematic representation of human USP11 (top) and KEAP1 (bottom) gene 
organization and targeting sites of sgRNAs (as described in Extended Data Figure 1a) used to 
generate the USP11Δ and USP11Δ /KEAP1Δ  293T cells. The indels introduced by the 
CRISPR/Cas9 and their respective frequencies are indicated. The USP11 knockout was created 
first and subsequently used to make the USP11Δ /KEAP1Δ  double mutant. d, 
Immunoprecipitation (IP) of PALB2 from extracts prepared from 293T cells transfected with the 
indicated siRNA and with or without CPT (200 nM) treatment. IP with normal IgG was 
performed as a control. 
 
Extended Data Figure 9 | Related to Fig. 3.. a, U2OS DR-GFP cells were transfected with the 
indicated siRNAs or left untransfected (-). 24 h post-transfection, cells were transfected with an 
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I-SceI expression vector (circle). The percentage of GFP-positive cells was determined 48 h 
post-plasmid transfection for each condition and was normalized to the I-SceI + non-targeting 
(CTRL) condition (mean ± s.d., N=3). b,  Parental 293T cells or a USP11Δ derivative were 
transfected with the indicated GFP-PALB2 constructs, treated with CPT and processed for GFP 
immunoprecipitation (IP). c, Parental 293T cells (WT) or a USP11Δ derivative were transfected 
with an empty vector (EV) or the indicated PALB2 expression vectors. Sensitivity of the cells to 
the PARP inhibitor Olaparib was then determined by a clonogenic survival assay (mean ± s.d., 
N=3). 
 
Extended Data Figure 10 | Related to Fig. 3. a, U2OS cells synchronized in G1 or S/G2 were 
treated with cyclohexamide (CHX) and processed at the indicated time points to monitor USP11 
stability. b, Immunoprecipitation (IP) of PALB2 from extracts prepared from 293T cells that 
were synchronized in G1 or S phase and treated or not with IR (20 Gy). c, U2OS cells were 
irradiated with a dose of 2 or 20 Gy and processed for USP11 immunoblotting at the indicated 
times post-IR. Actin was used as a loading control. d, U2OS cells, mock-treated or incubated 
with the ATM (KU55933; ATMi), ATR (VE-821; ATRi) or DNA-PKcs (NU7441; DNAPKi) 
inhibitors, were irradiated (20 Gy) and processed for USP11 and actin (loading control) 
immunoblotting. e, Similar experiment to d except that cells were UV-irradiated with a 50 
mJ/cm2 dose. f, U2OS cells, mock-treated or incubated with the proteasome inhibitor MG132, 
were irradiated (20 Gy) and processed for USP11 and actin (loading control) immunoblotting. g, 
U2OS cells, mock-treated or incubated with the Cullin inhibitor MLN4924, were irradiated (20 
Gy) and processed for USP11 and actin (loading control) immunoblotting.  
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Extended Data Figure 11 | Related to Fig. 3. 53BP1Δ U2OS cells were transfected with the 
indicated siRNA, synchronized in G1 or S/G2 by release from a double-thymidine block and 
irradiated (20 Gy) before being processed for fluorescence microscopy. DAPI was used to trace 
the nuclear boundary and Cyclin A staining was used to determine cell cycle position. The 
percentage of cells with more than 5 γ-H2AX-colocalizing PALB2 foci is indicated as the 
mean ± s.d., N=3. Scale bar = 5 µm. 
 
Extended Data Figure 12 | Related to Fig. 4. a, Representative micrographs of irradiated G1-
synchronized wild-type (WT) and 53BP1Δ U2OS cells transfected with the indicated siRNA and  
expressing wild-type (WT) CtIP.  b, Representative micrographs of irradiated G1-synchronized 
53BP1ΔU2OS cells transfected with the indicated siRNA and expressing CtIP-T847E. c, 
Micrograph of a U2OS cell targeted with the mClover system showing the typical perinuclear 
expression pattern of Lamin A. d, Micrograph of a U2OS cell targeted with the mClover system 
showing an expression pattern characteristic of subnuclear PML foci. e, Timeline of the gene 
targeting (LMNA) experiment presented in Fig 4e. f, Timeline of the gene targeting (LMNA or 
PML) experiment presented in Fig 4f and Extended Data Figure 13.  
 
Extended Data Figure 13 | Related to Fig. 4. a, Quantitation of gene targeting efficiency at the 
LMNA locus in asynchronously dividing cells transfected with the indicated siRNA. Gene 
targeting events were detected by flow cytometry (mean ± s.d., N=3). b, Gene targeting 
efficiency at the PML locus measured by flow cytometry in G1-arrested 53BP1Δ U2OS cells 
expressing the CtIP-T847E mutant and co-transfected with the indicated siRNA or a PALB2-KR 
expression construct (mean ± s.d., N=3). c, Representative FACS profiles showing the gating for 
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1N DNA content cells and the detection of mClover-positive cells in the LMNA gene targeting 
assay in asynchronous (ASN) or G1-arrested 53BP1Δ U2OS cells expressing the CtIP-T847E 
mutant and co-transfected with the indicated siRNA or a PALB2-KR expression construct. 
 
Extended Data Figure 14 | Related to Fig. 4. a, Gene targeting efficiency at the LMNA locus 
measured by flow cytometry in G1-arrested parental (WT) and 53BP1Δ U2OS cells transfected 
with KEAP1 siRNA and expressing the CtIP-T847E mutant (mean ± s.d., N=3). b, Gene 
targeting efficiency at the LMNA locus measured by flow cytometry in G1-arrested parental 
(WT) and 53BP1Δ U2OS cells transfected with the indicated siRNA and expressing either wild-
type (WT) or the CtIP-T847E mutant (mean ± s.d., N=3).  
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METHODS 
 
Plasmids 
The cDNA of PALB2 was obtained from the Mammalian Gene Collection (MGC). Full length 
PALB2 and BRCA1 were amplified by PCR, subcloned into pDONR221 and delivered into the 
pDEST-GFP, pDEST-Flag and the mCherry-LacR vectors using Gateway cloning technology 
(Invitrogen). Similarly, the coiled-coil domain of BRCA1 was amplified by PCR, subcloned into 
the pDONR221 vector and delivered into both mCherryLacR and pDEST-GFP vectors. The N-
terminal domain of PALB2 was amplified by PCR and introduced into the GST expression 
vector pET30-2-His-GST-TEV31 using the EcoRI/XhoI sites. The coiled-coil domain of BRCA1 
was cloned into pMAL-c2 using the BamHI/SalI sites. Truncated forms of PALB2 were obtained 
by introducing stop codons or deletions through site-directed mutagenesis. Full-length CtIP was 
amplified by PCR, subcloned into the pDONR221 and delivered into the lentiviral construct 
pCW57.1 (a kind gift of Dr. David Root; Addgene plasmid #41393) using Gateway cloning 
technology (Invitrogen). The USP11 cDNA was a kind gift of David Cortez and was amplified 
by PCR and cloned into the pDsRed2-C1 vector using the EcoRI/SalI sites. The bacterial codon-
optimised coding sequence of pig USP11 (USP11) was subcloned into the 6xHis-GST vector 
pETM-30-Htb using the BamHI/EcoRI sites. siRNA-resistant versions of PALB2, BRCA1 and 
USP11 constructs were generated as previously described (11). Full-length CUL3 and RBX1 
were amplified by PCR from a human pancreas cDNA library (Invitrogen) as previously 
described32 and cloned into the dual expression pFBDM vector using NheI/XmaI and 
BssHII/NotI respectively. The NEDD8 cDNA was a kind gift of Dmitris Xirodimas and was 
fused to a double StrepII tag at its C-terminus in the pET17b vector (Millipore). Human DEN1 
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was amplified from a vector supplied by Aude Echalier and fused to a non-cleavable N-terminal 
StrepII2x tag by PCR and inserted into a pET17b vector. The pCOOL-mKEAP1 plasmid was a 
kind gift from Dr. Feng Shao. The pcDNA3-HA2-KEAP1 and pcDNA3-HA2-KEAP1ΔBTB 
were kind gifts from Dr. Yue Xiong (Addgene plasmids #21556 and 21593). gRNAs were 
synthesized and processed as described previously33. Annealed gRNAs were cloned into the 
Cas9-expressing vectors pSpCas9(BB)-2A-Puro (PX459) or pX330-U6-Chimeric_BB-CBh-
hSpCas9, a kind gift from Feng Zhang (Addgene plasmids #48139 and 42230). The gRNAs 
targeting the LMNA or the PML locus and the mClover-tagged LMNA or PML are from Pinder et 
al (submitted). The lentiviral packaging vector psPAX2 and the envelope vector VSV-G were a 
kind gift from Didier Trono (Addgene plasmids #12260 and 12259). 6xHis-Ubiquitin was cloned 
into the pcDNA5-FRT/TO backbone using the XhoI/HindIII sites. All mutations were introduced 
by site-directed mutagenesis using QuikChange (Stratagene) and all plasmids were sequence-
verified. 
 
Cell culture and plasmid transfection 
All culture media were supplemented with 10% fetal bovine serum (FBS). U-2-OS (U2OS) cells 
were cultured in McCoy’s medium (Gibco). 293T cells were cultured in DMEM (Gibco). 
Parental cells were tested for mycoplasma contamination and authenticated by STR DNA 
profiling. Plasmid transfections were carried out using Lipofectamine 2000 Transfection Reagent 
(Invitrogen) following the manufacturer’s protocol. Lentiviral infection was carried out as 
previously described18. 
 
Antibodies  
 26 
We employed the following antibodies: rabbit anti-53BP1 (A300-273A, Bethyl), rabbit anti-
53BP1 (sc-22760, Santa Cruz), mouse anti-53BP1 (#612523, BD Biosciences), mouse anti-γ-
H2AX (clone JBW301, Millipore), rabbit anti-γ-H2AX (#2577, Cell Signaling Technologies), 
rabbit anti-KEAP1 (ab66620, Abcam), rabbit anti-NRF2 (ab62352, Abcam), mouse anti-Flag 
(clone M2, Sigma), mouse anti-tubulin (CP06, Calbiochem), mouse anti-GFP (#11814460001, 
Roche), mouse anti-CCNA (MONX10262, Monosan), rabbit anti-BRCA2 (ab9143, Abcam), 
mouse anti-BRCA2 (OP95, Calbiochem), rabbit anti-BRCA1 (#07-434, Millipore), rabbit anti-
USP11 (ab109232, Abcam), rabbit anti-USP11 (A301-613A, Bethyl), rabbit anti-RAD51 (#70-
001, Bioacademia), mouse anti-BrdU (RPN202, GE Healthcare), mouse anti-FK2 (BML-
PW8810, Enzo), rabbit anti-PALB234, rabbit anti-GST (sc-459, Santa Cruz), rabbit anti-CUL3 
(A301-108A, Bethyl), mouse anti-MBP (E8032, NEB), mouse anti-HA (clone 12CA5, a kind 
gift of Dr. M. Tyers), rabbit anti-Ubiquitin (Z0458, Dako) and mouse anti-actin (CP01, 
Calbiochem). The following antibodies were used as secondary antibodies in 
immunofluorescence microscopy: Alexa Fluor 488 donkey anti-rabbit IgG, Alexa Fluor 488 
donkey anti-goat IgG, Alexa Fluor 555 donkey anti-mouse IgG, Alexa Fluor 555 donkey anti-
rabbit IgG, Alexa Fluor 647 donkey anti-mouse IgG, Alexa Fluor 647 donkey anti-human IgG, 
Alexa Fluor 647 donkey anti-goat IgG (Molecular Probes). 
 
RNA interference 
All siRNAs employed in this study were single duplex siRNAs purchased from ThermoFisher. 
RNAi transfections were performed using Lipofectamine RNAiMax (Invitrogen) in a forward 
transfection mode. The individual siRNA duplexes used were: BRCA1 (D-003461-05), PALB2 
(D-012928-04), USP11 (D-006063-01), CUL1 (M-004086-01), CUL2 (M-007277-00), CUL3 
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(M-010224-02), CUL4A (M-012610-01), CUL4B (M-017965-01), CUL5 (M-019553-01), 
KEAP1 (D-12453-02), RAD51 (M-003530-04), CtIP/RBBP8 (M-001376-00), BRCA2 (D-
003462-04), 53BP1 (D-003549-01) and non-targeting control siRNA (D-001210-02). Except 
when stated otherwise, siRNAs were transfected 48 h prior to cell processing.   
 
Inhibitors and fine chemicals 
We employed the following drugs at the indicated concentration and time: cycloheximide (CHX; 
Sigma) at 100 ng/mL, camptothecin (CPT; Sigma) at 0.2 µM, ATM inhibitor (KU55933; Selleck 
Chemicals) at 10 µM, ATR inhibitor (VE-821; kind gift of Philip Reaper) at 10 µM, DNA-PKcs 
inhibitor (NU7441; Genetex) at 10 µM, proteasome inhibitor MG132 (Sigma) at 2 µM, 
Lovastatin (S2061; Selleck Chemicals) at 40 µM, Doxycycline (#8634-1; Clontech), Nedd8-
activating enzyme inhibitor (MLN4929; Active Biochem) at 5 µM and olaparib (Selleck) at the 
indicated concentrations.   
 
Immunofluorescence microscopy 
In most cases, cells were grown on glass coverslips, fixed with 2% (w/v) paraformaldehyde in 
PBS for 20 min at room temperature, permeabilized with 0.3 % (v/v) Triton X-100 for 20 min at 
room temperature and blocked with 5% BSA in PBS for 30 min at room temperature. 
Alternatively, cells were fixed with 100% cold methanol for 10 min at -20°C and subsequently 
washed with PBS for 5 min at room temperature before PBS-BSA blocking. Cells were then 
incubated with the primary antibody diluted in PBS-BSA for 2 h at room temperature. Cells were 
next washed with PBS and then incubated with secondary antibodies diluted in PBS-BSA 
supplemented with 0.8 µg/ml of DAPI to stain DNA for 1 h at room temperature. The coverslips 
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were mounted onto glass slides with Prolong Gold mounting agent (Invitrogen). Confocal 
images were taken using a Zeiss LSM780 laser-scanning microscope. For G1 vs. S/G2 analysis 
of the BRCA1-PALB2-BRCA2 axis, cells were first synchronized with a double-thymidine 
block, released to allow entry into S phase and exposed to 2 or 20 Gy of X-irradiation at 5h and 
12h post-release and fixed at 1 to 5 hours post-treatment (where indicated). For the examination 
of DNA replication, cells were pre-incubated with 30 µM BrdU for 30 min before irradiation and 
processed as previously described. 
 
 CRISPR/Cas9 genome editing of USP11/KEAP1 
293T and U2OS cells were transiently transfected with 3 distinct sgRNAs targeting either 
53BP1, USP11 or KEAP1 and expressed from the pX459 vector containing Cas9 followed by 
the 2A-Puromycin cassette. The next day, cells were selected with puromycin for 2 days and 
subcloned to form single colonies or subpopulations. Clones were screened by immunoblot 
and/or immunofluorescence to verify the loss of 53BP1, USP11 or KEAP1 expression and 
subsequently characterized by PCR and sequencing. The genomic region targeted by the 
CRISPR/Cas9 was amplified by PCR using Turbo Pfu polymerase (Agilent) and the PCR 
product was cloned into the pCR2.1 TOPO vector (Invitrogen) before sequencing. 
 
Olaparib clonogenic assay 
293T cells were incubated with the indicated doses of olaparib (Selleck Chemicals) for 24 h, 
washed once with PBS and counted by trypan blue staining. 500 cells were then plated in 
duplicate for each condition. The cell survival assay was performed as previously described35.  
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Recombinant protein production  
GST and MBP fusions proteins were produced as previously described36,37. Briefly, MBP 
proteins expressed in Escherichia coli were purified on amylose resin (New England Biolabs) 
according to the batch method described by the manufacturer and stored in 1X PBS, 5% 
glycerol. GST proteins expressed in E. coli were purified on glutathione sepharose 4B (GE 
Healthcare) resin in 50 mM Tris HCl pH 7.5, 300 mM NaCl, 2 mM DTT, 1 mM EDTA, 15 
µg/mL AEBSF and 1x Complete protease inhibitor cocktail (Roche). Upon elution from the resin 
using 50 mM glutathione in 50 mM Tris HCl pH 8, 2 mM DTT, the His6-GST tag was cleaved 
off using His-tagged TEV protease (kindly provided by F. Sicheri) in 50 mM Tris HCl pH 7.5, 
150 mM NaCl, 10 mM glutathione, 10% glycerol, 2 mM sodium citrate and 2 mM β-
mercaptoethanol. His6-tagged proteins were depleted using Ni-NTA-agarose beads (Qiagen)  in 
50 mM Tris HCl pH 7.5, 300 mM NaCl, 20 mM imidazole, 5 mM glutathione, 10% glycerol, 1 
mM sodium citrate and 2 mM β-mercaptoethanol followed by centrifugal concentration (Amicon 
centrifugal filters, Millipore). GST-mKEAP1 was purified as described previously38, with an 
additional anion exchange step on a HiTrap Q HP column (GE Healthcare). The GST tag was 
left on the protein for in vitro experiments. Purification of CUL3 and RBX1 was performed as 
previously described32. Nedd8 and Den1 were expressed in E.coli BL21 grown in Terrific broth 
media and induced overnight with 0.5 mM IPTG at 16°C. Cells were harvested and resuspended 
in wash buffer (400 mM NaCl, 50 mM Tris-HCl, pH 8, 5% glycerol, 2 mM DTT), supplemented 
with lysozyme, universal nuclease (Pierce), benzamidine, leupeptin, pepstatin, PMSF and 
Complete protease inhibitor cocktail (Roche), except for Dcn1-expressing cells where the 
protease inhibitors were omitted. Cells were lysed by sonication and the lysate was cleared by 
centrifugation at 20,000 rpm for 50 min. The soluble supernatant was bound to a 5 ml Strep-
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Tactin Superflow Cartridge with a flow rate of 3 ml/min using a peristaltic pump. The column 
was washed with 20 column volumes (CV) of washing buffer and eluted with 5 CV washing 
buffer, diluted 1:2 in water to reduce the final salt concentration, and supplemented with 2.5 mM 
desthiobiotin. The elution fractions were pooled and concentrated to a total volume of 4 ml using 
a 3 kDa cut-off Amicon concentrator. Den1 was further purified over a Superdex 75 size 
exclusion column, buffer exchanged into 150 mM NaCl, HEPES, pH 7.6, 2 % glycerol and 1 
mM DTT. The C-terminal pro-peptide and StrepII2x-tag were removed by incubation with 
StrepII2x-Dcn1 in 1:20 molar ratio for 1 hour at room temperature. The Den1 cleavage reaction 
was buffer exchanged on a Zeba MWCO desalting column (Pierce), to remove the desthiobiotin, 
and passed through a Strep-Tactin Cartridge, which retains the C-terminal pro-peptide and Den1. 
GST-USP11 proteins were expressed in E. coli as described{Hendriks, 2015 #6222}. Cells were 
lysed by lysozyme treatment and sonication in 50mM Tris pH 7.5, 300mM NaCl, 1mM EDTA, 
1mM AEBSF, 1 x Protease Inhibitor mix (284 ng/ml leupeptin, 1.37 µg/ml pepstatin A, 170 
µg/ml PMSF and 330 µg/ml benzamidine) and 5% glycerol. Cleared lysate was applied to a 
column packed with glutathione sepharose 4B (GE Healthcare), washed extensively with lysis 
buffer before elution in 50mM Tris pH 7.5, 150mM NaCl, 5% glycerol and 25mM reduced 
glutathione. DUB activity was assayed on fluorogenic Ubiquitin-AMC, measured using a 
Synergy Neo microplate reader (Biotek). 
 
In vitro ubiquitylation and deubiquitylation of PALB2  
HA-tagged N-terminal fragments of PALB2 (1-103) (1 µM) were in vitro ubiquitylated using 50 
µM wild-type (Ubi WT, Boston Biochem) or a lysine-less ubiquitin (Ubi K0, Boston Biochem), 
100 nM human Uba1 (E1), 500 nM CDC34 (kindly provided by F. Sicheri and D. Ceccarelli), 
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250 nM neddylated CUL3/RBX1, 375 nM GST-mKEAP1 and 1.5 mM ATP in a buffer 
containing 50 mM Tris HCl pH 7.5, 20 mM NaCl, 10 mM MgCl2 and 0.5 mM DTT. 
Ubiquitylation reactions were carried out at 37 ºC for 1 hour, unless stated otherwise. For 
USP11-mediated deubiquitylation assays, HA-PALB2 (1-103) was first ubiquitylated using 
lysine-less ubiquitin with enzyme concentrations as described above in 50 µL reactions in a 
buffer containing 25mM HEPES pH 8, 150 mM NaCl, 10 mM MgCl2, 0.5 mM DTT and 1.5 mM 
ATP for 1.5 h at 37 ºC. Reactions were stopped by the addition of 1 unit Apyrase (New England 
Biolabs).  Reaction products were mixed at a 1:1 ratio with wild-type or catalytically inactive 
(C270S) USP11, or USP2 (kindly provided by Dr. F. Sicheri and E. Zeqiraj) using final 
concentrations of 100 nM – 500 nM – 2500 nM (USP11) and 500 nM (USP2) and incubated for 
2 h at 30 ºC in a buffer containing 25 mM Hepes pH 8, 150 mM NaCl, 2 mM DTT, 0.1 mg/mL 
BSA, 0.03% Brij-35, 5 mM MgCl2, 0.375 mM ATP.  
 
Pulldown experiments between purified PALB2 and BRCA1 
PALB2 in vitro ubiquitylation reaction products were diluted in a buffer at final concentration of 
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 0.25 mM DTT and 0.1% NP-40. 20 µg 
MBP or MBP-BRCA1-CC (coiled coil region of BRCA1) was coupled to amylose resin (New 
England Biolabs) in the above buffer supplemented with 0.1% BSA prior to addition of the 
ubiquitylation products. Pulldown reactions were performed at 4 ºC for 2 h, followed by 
extensive washing. 
 
Co-immunoprecipitation  
Cells were collected by trypsinization, washed once with PBS and lysed in 500 µL of lysis buffer 
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(20 mM Tris-HCl pH 8.0, 150 mM NaCl, 10% glycerol, 2 mM EDTA, 1% NP-40, Complete 
protease inhibitor cocktail (Roche), cocktail of phosphatase inhibitors (Sigma) and N-
ethylmaleimide to inhibit deubiquitination) on ice. Lysates were centrifuged at 15 000 g for 10 
min at 4°C and protein concentration was evaluated using absorbance at 280 nm. Equivalent 
amounts of proteins (~0.5-1 mg) were incubated with 2 µg of rabbit anti-PALB2, rabbit anti-
USP11 antibody, rabbit anti-GFP antibody or normal rabbit IgG for 5 h at 4°C. A mix of protein 
A/protein G-Sepharose beads (Thermo Scientific) was added for an additional hour. Beads were 
collected by centrifugation, washed twice with lysis buffer and once with PBS, and eluted by 
boiling in 2X Laemmli buffer before analysis by SDS-PAGE and immunoblotting.  
 
Mass spectrometry 
Following immunoprecipitation of transiently transfected Flag-PALB2 from siCTRL-transfected 
or USP11 siRNA-depleted 293T cells, cysteine residues were reduced and alkylated using DTT 
and 2-chloroacetamide, respectively. Proteins were digested using limited trypsin digestion on 
beads (1 µg trypsin (Worthington, NJ, USA) per sample, 20 min at 37ºC), and dried to 
completeness. For LC-MS/MS analysis, peptides were reconstituted in 5% formic acid and 
loaded onto a 12-15 cm fused silica column with pulled tip packed in-house with 3.5 µm Zorbax 
C18 (Agilent Technologies, CA, USA). Samples were analyzed using an Orbitrap Velos 
(Thermo Scientific, MA, USA) coupled to an Eksigent nanoLC ultra (AB SCIEX, CA). Peptides 
were eluted from the column using a 90 min period cycle with a linear gradient from 2% to 35% 
acetonitrile  in 0.1% formic acid. Tandem MS spectra were acquired in a data-dependent mode 
for the top two most abundant and five most specific N-terminal PALB2 tryptic digest peptides, 
either in non-modified form or including a diGly-ubiquitin trypsin digestion remnant. Tandem 
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MS spectra were acquired using collision-induced dissociation. Spectra were searched against 
the human Refseq_V53 database using Mascot, allowing up to 4 missed cleavages and including 
carbamidomethyl (C), deamidation (NQ), oxidation (M), GlyGly (K) and LeuArgGlyGly (K) as 
variable modifications.  
 
In vitro ubiquitylated HA-PALB2 (1-103) (50 µL reactions) was in-gel reduced using DTT, 
alkylated using 2-chloroacetamide and trypsin digested for 16 h at 37 ºC. Digested peptides were 
mixed with 20 µL of a mix of 10 unique heavy isotope-labeled N-terminal PALB2 peptides 
(Table 1, 80-1200 fmol/µL per peptide, based on individual peptide sensitivity testing) before 
loading 6 µL onto a 12-15 cm fused silica column with pulled tip packed in-house with 3.5 µm 
Zorbax C18. Samples were measured on an Orbitrap ELITE (Thermo Scientific, MA, USA) 
coupled to an Eksigent nanoLC ultra (AB SCIEX, CA, USA). Peptides were eluted from the 
column using a 180 min period cycle with a linear gradient from 2% to 35% acetonitrile in 0.1% 
formic acid. Tandem MS spectra were acquired in a data-dependent mode for the top two most 
abundant and ten N-terminal PALB2 tryptic digest peptides, either in light or heavy isotope-
labeled form. Tandem MS spectra were acquired using collision induced dissociation. Spectra 
were searched against the human Refseq_V53 database using Mascot, allowing up to 2 missed 
cleavages and including carbamidomethyl (C), deamidation (NQ), oxidation (M), GlyGly (K) 
and LeuArgGlyGly (K) as variable modifications, after which spectra were manually checked. 
 
 
His-Ubiquitin pull-down 
293 FLIP-IN cells stably expressing His-Ub were transfected with the indicated siRNA and 
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treated with doxycycline (DOX) for 24hrs to induce Ub expression. Cells were pre-treated with 
10 mM N-ethylmaleimide for 30 min and lysed in denaturating lysis buffer (6 M guanidinium-
HCl, 0.1 M Na2HPO4/NaH2PO4, 10 mM Tris-HCl, 5 mM imidazole, 0.01 M β-mercaptoethanol, 
Complete protease inhibitor cocktail). Lysates were sonicated on ice twice for 10 sec with 1 min 
break and centrifuged at 15 000 g for 10 min at 4°C. The supernatant was incubated with Ni-
NTA-agarose beads (Qiagen) for 4 h at 4°C. Beads were collected by centrifugation, washed 
once with denaturating lysis buffer, once with wash buffer (8 M Urea, 0.1 M 
Na2HPO4/NaH2PO4, 10 mM Tris-HCl, 5 mM imidazole, 0.01 M β -mercaptoethanol, Complete 
protease inhibitor cocktail), and twice with wash buffer supplemented with 0.1% Triton X-100, 
and eluted in elution buffer (0.2 M imidazole, 0.15 M Tris-HCl, 30% glycerol, 0.72 M β -
mercaptoethanol, 5% SDS) before analysis by SDS-PAGE and immunoblotting.  
 
HR-based repair assays 
Parental U2OS cells and U2OS cells stably expressing wild-type CtIP or CtIP-T847E mutant 
were transfected with the indicated siRNA and the PALB2-KR construct, synchronized with a 
single thymidine block, treated with doxycycline to induce CtIP expression and subsequently 
blocked in G1 phase by adding 40 µM Lovastatin. Cells were collected by trypsinization, washed 
once with PBS and electroporated with 2.5 µg of sgRNA plasmid and 2.5 µg of donor template 
using the Nucleofector technology (Lonza; protocol X-001). Cells were plated in medium 
supplemented with 40 µM Lovastatin and grown for 24hrs before flow cytometry analysis. 
 
PALB2 chemical ubiquitylation  
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PALB2 (1-103) polypeptides, engineered with only one cross-linkable cysteine, were 
ubiquitylated by cross-linking alkylation, as previously described40, with the following 
modifications. Purified PALB2 cysteine mutant (final concentration of 600uM) was mixed with 
6xHis-TEV-Ubiquitin G76C (350 µM) in 300 mM Tris pH 8.8, 120 mM NaCl and 5% glycerol. 
Tris(2-carboxyethyl)phosphine (TCEP) (Sigma-Aldrich) reducing agent was added to a final 
concentration of 6mM and the mixture and incubated for 30 minutes at room temperature. The 
bi-reactive cysteine cross-linker, 1,3-dichloroacetone (Sigma-Aldrich), was dissolved in 
dimethylformamide and added to the protein mix to a final concentration of 5.25 mM. The 
reaction was allowed to proceed on ice for 1 hr, before being quenched by the addition of 5 mM 
β-mercaptoethanol. His6-TEV-Ubiquitin-conjugated PALB2 was enriched by passing over Ni-
NTA-agarose beads (Qiagen). 
 
Table 1: Heavy isotope-labeled N-terminal PALB2 tryptic peptides 
Sequence Label* Position in protein Concentration in final mix m/z (1+) 
EKLKEK Leu-3 15-20 800 fmol/ µL 781.4891 
EK(diG)LKEK Leu-3 15-20 (K16_ubi) 480 fmol/ µL 895.5321 
AQRAEKIK Arg-3 38-45 800 fmol/ µL 953.5766 
AQRAEK(diG)IK Arg-3 38-45 (K43_ubi) 400 fmol/ µL 1067.6195 
LAFLK Leu-4 21-25 80 fmol/ µL 598.4036 
LAFLKR Leu-4 21-26 800 fmol/ µL 754.5047 
LAFLK(diG)R Leu-4 21-26 (K25_ubi) 80 fmol/ µL 868.5477 
EYSK Lys-4 27-30 1200 fmol/ µL 534.265 
EYSKTLAR Leu-6 27-34 80 fmol/ µL 974.5379 
EYSK(diG)TLAR Leu-6 27-34 (K30_ubi) 80 fmol/ µL 1088.5808 
* Labels used: 13C15N-Arginine, 13C15N-Leucine, 13C15N-Lysine 
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Extended Data Table 1: Heavy isotope-labeled N-terminal PALB2 tryptic peptides 
Sequence Label* Position in 
protein 
Concentration in final 
mix 
m/z (1+) 
(heavy labeled) 
 m/z (1+) 
(unlabeled) 
EKLKEK Leu-3 15-20 800 fmol/ µL 781.4891 774.472 
EK(diG)LKEK Leu-3 15-20 
(K16_ubi) 
480 fmol/ µL 895.5321 888.5149 
AQRAEKIK Arg-3 38-45 800 fmol/ µL 953.5766 943.5683 
AQRAEK(diG)IK Arg-3 38-45 
(K43_ubi) 
400 fmol/ µL 1067.6195 1057.6113 
LAFLK Leu-4 21-25 80 fmol/ µL 598.4036 591.3865 
LAFLKR Leu-4 21-26 800 fmol/ µL 754.5047 747.4876 
LAFLK(diG)R Leu-4 21-26 
(K25_ubi) 
80 fmol/ µL 868.5477 861.5305 
EYSK Lys-4 27-30 1200 fmol/ µL 534.265 526.2508 
EYSKTLAR Leu-6 27-34 80 fmol/ µL 974.5379 967.5207 
EYSK(diG)TLAR Leu-6 27-34 
(K30_ubi) 
80 fmol/ µL 1088.5808 1081.5636 
* Labels used: 13C15N-Arginine, 13C15N-Leucine, 13C15N-Lysine 
 
